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A B S T R A C T
Introduction: CVT-301 is an orally inhaled levodopa therapy approved for the intermittent treatment of OFF
episodes in Parkinson's disease patients who are taking a standard oral levodopa regimen. This open-label,
randomized, controlled study over 12 months characterizes the safety, including pulmonary safety, of CVT-301
84 mg (nominal respirable levodopa fine-particle dose, 50 mg).
Methods: Patients experiencing motor fluctuations were randomized 2:1 to CVT-301 or an observational cohort
(OC) receiving oral standard of care. Pulmonary safety was assessed using spirometry and carbon monoxide
diffusion capacity (DLCO). Exploratory efficacy endpoints, assessed only for CVT-301, included change in Unified
Parkinson's Disease Rating Scale Part III (UPDRS-III), patients achieving ON within 60 min and remaining ON at
60 min, Patient Global Impression of Change (PGIC) scale, and total daily OFF time.
Results: Of 408 patients randomized, 310 completed the study (204 in CVT-301 and 106 in OC). Mean 12-month
changes from baseline for CVT-301 were −0.105 L (FEV1) and −0.378 mL/min/mm Hg (DLCO), and for OC
were −0.117 L and −0.722 mL/min/mm Hg, respectively. Between-group comparisons were not statistically
significant. For FEV1/FVC the 12-month change was −0.3 and −1.6, respectively, which was a significant
between-group difference. However, between-group differences were not significant at 3 and 9 months and all
changes from baseline were small (< 2.0%). UPDRS-III scores improved from predose to 60 min postdose at all
assessments; 80%–85% of patients switched ON within 60 min and remained ON; and>75% reported im-
provement in PGIC. OFF time decreased by 1.32–1.42 h/day.
Conclusion: CVT-301 84 mg induced no clinically significant differences in pulmonary function compared with
the OC. Improvements in motor scores, OFF time, and patient-reported outcomes support clinical efficacy for up
to 12 months.
1. Introduction
Levodopa (LD) administered orally with a dopa decarboxylase in-
hibitor (DDI) such as carbidopa is the most effective treatment for
managing the motor symptoms of Parkinson's disease (PD) [1–3].
However, ON-OFF fluctuations become increasingly frequent with
chronic LD exposure and disease progression [3–5].
CVT-301 (Inbrija™) is a self-administered, orally inhaled therapy
approved for the intermittent treatment of OFF-period symptoms in
patients with PD who are taking an oral carbidopa/LD regimen [6–8].
Inhaled LD, which bypasses the gastrointestinal route, enters the
bloodstream rapidly and predictably [8]. In a double-blind, placebo-
controlled phase 3 study in patients on standard PD therapy, CVT-301
84 mg (nominal respirable LD fine-particle dose, 50 mg) significantly
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improved the Unified Parkinson's Disease Rating Scale Part III (motor)
(UPDRS-III) score at 30 min postdose at week 12 compared with pla-
cebo [7]. A greater percentage of patients treated with CVT-301 (58%)
experienced and maintained an ON response through 60 min after
dosing compared with placebo (36%) [7]. In 2 phase 2 studies, pul-
monary safety and tolerability of CVT-301 were evaluated in PD pa-
tients experiencing motor fluctuations [9,10]. Spirometry assessments
were within normal ranges at screening, and showed no significant
difference between CVT-301 and placebo over 4 weeks [10].
Pulmonary safety of an inhaled therapy is important given ex-
pectation of long-term use for management of PD OFF symptoms. This
12-month, open-label, randomized, observational cohort (OC)-con-
trolled study of PD patients experiencing motor fluctuations was de-
signed primarily to evaluate the long-term pulmonary safety of CVT-
301 84 mg as an adjunct to an oral DDI/LD therapeutic regimen for up
to 12 months, while supporting, via an open-label, uncontrolled ap-
proach, previous efficacy and tolerability results.
2. Methods
2.1. Study population
Eligibility criteria included idiopathic PD, diagnosed after age 30
years; modified Hoehn and Yahr stage [11] 1 to 3 (in the ON state);
≥2 h of average daily OFF time (excluding early-morning OFF time);
taking a stable oral DDI/LD regimen with ≥3 daily doses and total
daily LD dose ≤1600 mg; UPDRS-III improvement ≥25% from OFF to
ON at screening; Mini-Mental State Examination [12] score ≥25; no
dyskinesia interfering with study procedures; and no chronic re-
spiratory disease within the last 5 years. Patients had to be able to
perform spirometry in both ON and OFF states and to have FEV1 (forced
expiratory volume in 1 s) ≥50% of predicted volume, and FEV1/FVC
(forced vital capacity) ratio> 60% in the ON state at screening. Pa-
tients were CVT-301-naïve, except for 3 patients who were enrolled
from phase 2 studies under an early version of the protocol.
The study (NCT02352363) was conducted at 8 sites in the United
States, 50 sites in Europe and 4 sites in Israel, and was performed in
accordance with the Declaration of Helsinki. All sites received institu-
tional review board approval, and patients provided written informed
consent.
2.2. Assessments
The primary objective of this study was to characterize pulmonary
safety, as assessed by spirometry, over a 12-month period in CVT-301-
treated patients. The primary outcome measures were FEV1, FVC,
FEV1/FVC ratio, and diffusing capacity of the lungs for carbon mon-
oxide (DLCO) assessed over the 12-month period, with a negative
change indicating a decline in pulmonary function. While FEV1, FVC,
and FEV1/FVC ratio allow for determination of obstructive or restrictive
lung disease, DLCO is a measure of gas exchange across the alveolar-
capillary membrane [13].
Nonpulmonary safety assessments included dyskinesia occurrence
and severity (mild, moderate, or severe) during the 60-min postdose
period at each visit as recorded by the investigator. Other safety as-
sessments were adverse events (AEs), serious AEs, clinical laboratory
values, routine and orthostatic vital signs, electrocardiograms (ECGs),
and physical examination. In addition, assessments of suicidality
(Columbia-Suicide Severity Rating Scale [14]), somnolence (Epworth
Sleepiness Scale [15]), and impulse control behaviors (Questionnaire
for Impulsive-Compulsive Disorders in Parkinson's Disease [16]) were
performed.
Exploratory efficacy assessments, performed on the CVT-301 cohort
only, included UPDRS-III scores, Patient Global Impression of Change
(PGIC) scale, and the occurrence of an ON state during the 60 min
postdose as assessed by the investigator (a binary assessment of ON or
OFF).
2.3. Study design
Eligible patients were randomized 2:1 using an interactive web re-
sponse system to CVT-301 84 mg or to the OC, in which patients re-
ceived standard oral PD treatment. Randomization was stratified by
Hoehn and Yahr scale rating category (< 2.5 versus ≥2.5), as mea-
sured in the ON state, to balance the disease severity in each group, and
by screening spirometry results (FEV1< 60% of predicted and FEV1/
FVC ratio< 70%, versus FEV1 ≥60% of predicted and FEV1/FVC ratio
≥70%). Testing was performed in accordance with the American
Thoracic Society/European Respiratory Society criteria [17] before
randomization.
The study included a screening period lasting up to 35 days and a
treatment period of approximately 12 months, with study visits at
baseline, 1, 3, 6, 9, and 12 months, plus a follow-up at a pulmonary
function facility 1 month after the last visit (Fig. 1A). Spirometry and
DLCO assessments were performed at a dedicated pulmonary function
facility within 2 weeks before baseline; at 3-, 6-, 9-, and 12-month
visits; and at the follow-up visit. Pulmonary safety results for the CVT-
301 group were compared with those from the OC. Spirometry and
DLCO assessments were performed when patients were in the ON state.
Exploratory efficacy measurements in the CVT-301 cohort were
taken at baseline and months 1, 3, 6, 9, and 12. UPDRS-III assessments
were performed for all patients immediately predose; and at 10, 20, 30,
and 60 min postdose. Patients completed the PGIC on arrival at each
visit, preferably while in the ON state. Patients also recorded in a PD
diary [18] their waking ON/OFF status (time OFF, time ON without
dyskinesia, time ON with non-troublesome dyskinesia, time ON with
troublesome dyskinesia) and their time asleep during the 3 consecutive
days before each visit. Efficacy measurements were not taken in the OC.
2.4. Dosing
Patients were trained to use the inhaler and used CVT-301 ≤ 5
times/day when they began to experience OFF-period symptoms, ty-
pically indicated by return of PD motor symptoms. For some patients,
nonmotor symptoms heralded the onset of OFF periods shortly before
the appearance of motor symptoms. During the study visits, patients
self-administered their first dose of CVT-301 between 2 and 5 h after
oral LD medication, when the patient's OFF state was recognized by
both patient and investigator. The CVT-301 dose consisted of 2 cap-
sules, each containing 42 mg LD (a nominal 25 mg respirable LD fine-
particle dose), delivered sequentially using the oral breath-actuated
inhaler to provide a total of 84 mg (a nominal 50 mg fine-particle dose).
Patients used CVT-301 adjunctively with their stable PD medica-
tion, as a 2-capsule (i.e., 84 mg total) dose per treated OFF period. CVT-
301 was not used for treatment of early-morning OFF periods (morning
akinesia) because the effects of inhaled levodopa without current intake
of carbidopa were not known at the time of this study [19]. If a patient
developed significant tolerability concerns, a dose reduction from 2
capsules to 1 capsule was permitted. The patient then continued to use
1 capsule per OFF period for ≥1 week. If the tolerability issue resolved,
the patient could either resume taking the original 84-mg dose or could
receive a 60-mg reduced-dose kit (35 mg respirable fine-particle dose).
If a patient who had returned to the full 84-mg dose had another tol-
erability concern, the dose was reduced to 60 mg, and the patient re-
mained on 60 mg LD for the remainder of the study. In inhaled-dosing
logs, all patients recorded the number of times they used their inhaler
(and the number of capsules).
Patients could continue their usual standard baseline oral PD
medications throughout the study. In the CVT-301 group, however,
patients were not permitted to use other “rescue” medications such as
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apomorphine or additional on-demand doses of oral LD. Patients in the
OC did not use CVT-301.
2.5. Statistical analysis
The safety population was the same as the intent-to-treat population
and consisted of patients who received ≥1 dose of inhaled CVT-301 as
well as patients in the OC.
Changes in FEV1, FEV1/FVC ratio, and DLCO values within each
treatment group and differences between treatment groups were esti-
mated with a prespecified mixed-model for repeated measurements
(MMRM) analysis for all visits over the 12-month study period. The
model included the treatment group, visit, stratification variables, and
interaction between the treatment group and visit as fixed factors.
Baseline spirometry value was included as a covariate. Treatment dif-
ference was assessed with a 2-sided alpha level of 0.05. A sensitivity
analysis was performed using multiple imputation analysis based on
application of pattern-mixture models.
For continuous efficacy variables, within-group changes from
baseline were estimated using MMRM. No between-group differences
were calculated because efficacy assessments were obtained only for
the CVT-301 group. The model included the fixed factors of visit and
the stratification variables (Hoehn and Yahr stage and screening FEV1
and/or FEV1/FVC). Baseline value was used as a covariate. For cate-
gorical efficacy endpoints, variables were evaluated descriptively by
visit. Statistical evaluations were performed using Statistical Analysis
Software (SAS®) Version 9.3 or higher (SAS Institute, Cary, NC).
2.6. Sample size selection
The sample size was selected to meet the International Council for
Harmonization E1 guidelines to ensure that a minimum of 100 patients
in the CVT-301 group completed 12 months of treatment [20].
3. Results
First patient was enrolled April 8, 2015, and last patient visit was
May 16, 2017. Of the 513 patients screened, 408 were randomized, 278
to CVT-301 and 130 to the OC. Of the 105 screen failures, the primary
reasons were failure to meet pulmonary eligibility criteria or failure to
perform spirometry (34 patients, 32.4%). The study was completed by
204 patients in the CVT-301 group and 106 in the OC group (Fig. 1B).
Demographic and PD baseline characteristics were similar between
groups, except for mean daily LD dose, which was 874.1 (SD 348.3)
mg/day for the OC and 781.9 (357.7) mg/day for the CVT-301 group
(Table 1).
The mean duration of exposure was 308.9 (113) days for the CVT-
301 group, with 241 patients still receiving CVT-301 at 3 months,
227 at 6 months, 212 at 9 months, and 204 at 12 months. The average
number of daily doses was 2.33 (0.94) overall for CVT-301 patients.
The average CVT-301 usage did not change significantly over the course
of the study: usage was 2.33 doses/day (1.0) for the first 4 weeks and
2.40 doses/day (1.05) over the final 3 months. This represents a mean
LD dose of 201.6 mg or 120.0 mg respirable LD fine-particle dose over
the final 3 months. A total of 183 patients (67.5%) used 4 doses/day
(336.0 mg total/200.0 mg fine-particle dose) at least once, and 94 pa-
tients (34.7%) used 5 doses/day (420.0 mg/250 mg fine-particle dose)
at least once. Approximately 15% of all dosing days were at ≥4 doses/
day. The CVT-301 dose was decreased in 11 patients (4.1%) based on
tolerability concerns; of these, 6 patients (2.2%) eventually returned to
either 84 or 60 mg.
3.1. Pulmonary safety
At baseline, mean FEV1 was 2.84 L for both the CVT-301 and OC
groups, while FEV1/FVC values were 77.6 and 76.8, and mean DLCO
values were 23.3 and 23.7 mL/min/mm Hg, respectively. The mean
(SD) change from baseline in FEV1 at 12 months was −0.105 L (0.209)
for the CVT-301 group and −0.117 L (0.214) for the OC (Fig. 2A), with
Fig. 1. Study design (A) and patient disposition (B). Study visits occurred at 0, 1, 3, 6, 9, and 12 months. COPD, chronic obstructive pulmonary disease; DLCO,
diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; MMSE, Mini-Mental State Examination.
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a nonsignificant least-squares (LS) mean difference of 0.002 L (95% CI:
-0.046, 0.050), P = 0.936. The FEV1/FVC mean change from baseline
at 12 months was 0.5 (3.8) for the CVT-301 group and −0.5 (4.0) for
the OC. The LS mean change from baseline in FEV1/FVC at 12 months
was −0.3 (−1.0, 0.4) and−1.6 (−2.5, −0.8) for CVT-301 and the OC,
respectively, with this change being significantly greater in the OC
group, by 1.3 (0.5, 2.1), P= 0.002. The LS mean difference at 6 months
was also significant, at 0.8 (0.00, 1.5), P = 0.048. However, between-
group differences were not significant at the other assessment time
points (3 and 9 months), and all changes from baseline were numeri-
cally small (< 2.0%). Mean change from baseline at 12 months in DLCO
was −0.38 (2.27) for patients in the CVT-301 group and −0.72 (2.49)
for the OC (Fig. 2B), with an LS mean difference of 0.13 mL/min/mm
Hg (−0.42, 0.69), P = 0.637. Changes from baseline between the
groups were not significant at any visit. Mean spirometry values for
baseline and each visit are presented in esupp Table 1.
3.2. Adverse events
Twenty-eight of 271 patients (10.3%) randomized to CVT-301
treatment withdrew from the study because of an AE (Table 2). Of
these, 3 patients withdrew before administration of CVT-301, and 1
patient withdrew because of a preexisting AE of chronic lymphocytic
leukemia. Therefore, 24 patients (8.9%) in the CVT-301 group experi-
enced treatment-emergent AEs (TEAEs) that led to study withdrawal.
No study drug was administered in the OC, so no patients in the OC
withdrew due to a TEAE. Cough, which occurred in 3 patients, and
hallucination and bronchitis, which occurred in 2 patients, were the
only TEAEs that led to study withdrawal in more than 1 patient. Three
patients had> 1 AE given as the reason for withdrawal: 1 had AEs
of pulmonary embolism, dehydration, syncope, and rhabdomyolysis;
another had tachycardia, blurred vision, dry mouth, flushing,
hypertension, and bronchitis. The third patient had upper respiratory
tract irritation, salivary hypersecretion, nausea, and nasal congestion.
There was 1 death during the study: a patient in the CVT-301 treatment
group died from drowning (anoxia), which the investigator considered
to be not related to CVT-301. Serious AEs included urinary tract in-
fection, osteoarthritis, femoral neck fracture, back pain, inguinal
hernia, PD worsening, and dehydration. There were 2 serious AEs
possibly related to CVT-301: pulmonary embolism and dopamine dys-
regulation syndrome, which occurred in 1 patient each.
The most common AEs (≥5% in any cohort) were cough, naso-
pharyngitis, dyskinesia, and fall (Table 2). The most common CVT-
301‒related AEs were cough, dyskinesia, throat irritation, and dis-
colored sputum. Most TEAEs of cough were mild (38/43, 88.4%), and 1
event was severe. Three patients discontinued because of cough, and
28/36 (77.8%) of cough AEs started within the first 30 days of treat-
ment.
Among CVT-301-treated patients, the examiner-reported incidence
of dyskinesia during the 60-min postdose period at each clinic visit
generally decreased over time, from 55 patients (20.3%) at 1 month to
35 patients (12.9%) at 12 months. Most occurrences were mild or
moderate in severity, with 1–3 patients (0.4%–1.1%) experiencing se-
vere dyskinesia at a visit. Mean UPDRS Part IV dyskinesia total scores
showed no significant change (2.0 at baseline to 2.1 at 12 months). On
other safety measures, there were no CVT-301–associated effects for
suicidal ideation or behavior, no overall differences for impulsive-
compulsive disorders compared with OC, and no worsening in sleepi-
ness compared with OC. Orthostatic hypotension, measured predose at
each visit, affected 14.5% of CVT-301 and 14.9% of OC patients at 6
months, 10.4% and 15.3% at 9 months, and 15.4% and 9.3% at 12
months. Clinical laboratory tests, physical examinations, vital signs,
and ECG results were generally unremarkable and similar between
cohorts.
Table 1





Age, mean (range), years 64.2 (38–79) 63.6 (37–80)
Sex, male, % 61.4 59.4
Race, white, % 98.4 97.8
Height, mean (SD), cm 168.6 (9.4) 168.0 (8.9)
BMI, mean (range), kg/m2 26.9 (16.2–45.9) 27.2 (17.6–44.1)
Screening spirometry, FEV1 ≥60% and FEV1/FVC ≥70%, % 92.9 93.4
Modified Hoehn and Yahr stage, %
<2.5 47.2 46.9
≥2.5 52.8 53.1
Time since PD diagnosis, mean (SD), years 9.7 (5.2) 9.0 (4.8)
Number of daily OFF periods, mean (SD) 3.7 (1.0) 3.6 (1.1)
Daily OFF time, mean (SD), hours 5.7 (2.1) 5.6 (2.1)
Duration of LD treatment, mean (SD), years 7.3 (4.6) 7.2 (4.8)
Daily LD dose, mean (SD), mg 874.1 (348.3) 781.9 (357.7)
Number of daily LD doses, mean (SD) 5.2 (1.3) 5.1 (1.5)
Screening UPDRS-III total score, mean (SD)
OFF 38.0 (11.4) 37.8 (11.4)
ON 18.4 (9.1) 18.1 (8.9)
Other PD drug use, n (%)
Dopamine agonists 94 (74.0) 204 (75.3)
Ropinirole 50 (39.4) 93 (34.3)
Pramipexole 31 (24.2) 65 (24.0)
Rotigotine 12 (9.4) 39 (14.4)
Piribedil 1 (0.8) 3 (1.1)
Cabergoline 1 (0.8) 0
MAO-B inhibitors 45 (35.4) 111 (41.0)
Amantadine 37 (29.1) 80 (29.5)
Tertiary amines 10 (7.9) 12 (4.4)
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LD, levodopa; MAO-B, monoamine
oxidase B; PD, Parkinson's disease; UPDRS-III, Unified Parkinson's Disease Rating Scale Part III.
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3.3. Efficacy
Exploratory efficacy analysis of the change in UPDRS-III scores with
CVT-301 showed maximum improvement by 30 min and was sustained
through 60 min postdose (esupp Fig. 1A). Postdose mean UPDRS-III
changes were consistent from months 1–12. Eighty percent to 85% of
patients achieved ON within 60 min and remained ON at 60 min after a
single dose of CVT-301 (esupp Fig. 1B). PD diaries showed that re-
ductions in LS mean total daily OFF time were maintained over 12
months (esupp Fig. 1C). At months 3, 6, and 12, ≥75% of patients
reported improvement in PGIC (esupp Fig. 1D). Daily ON time without
dyskinesia improved from baseline at months 1 through 12 (LS mean
change 1.01–1.49 h) without notable changes in daily ON time with
non-troublesome or troublesome dyskinesia.
4. Discussion
This study represents the largest prospective evaluation of pul-
monary function in PD patients followed for up to 12 months, and it
was designed to assess the long-term safety of CVT-301. Comparable
declines in FEV1 and DLCO were noticed in CVT-301 and OC groups,
while FEV1/FVC ratio declined in the OC, but not in the CVT-301 group.
The annual decline in FEV1 in healthy nonsmoking individuals is ap-
proximately 30–40 mL and is age-dependent [21]. Participants in both
the CVT-301 group and the OC had a mutually consistent decrease in
FEV1 over the 1-year period that was approximately 3 times greater
than the expected decline in a non-PD population and may be due to
underlying PD-related factors. The randomized OC served an important
function in this study by demonstrating the lack of impact of CVT-301
administration on pulmonary function, in contrast to the contribution
of the natural progression of PD. A commonly accepted minimally
important difference for FEV1 in patients with COPD is 0.1 L, and the
treatment difference was −0.01 in this study [22]. No minimally im-
portant difference for FEV1/FVC has been described. For DLCO, the
minimally important difference in patients with COPD is 1.1 [23],
whereas the treatment difference in this study was 0.34, with the CVT-
301 group exhibiting a numerically smaller decline than the OC. Dry-
powder inhalers have been successfully employed in the delivery of
other active pharmaceutical ingredients [24], so this study shows that
CVT-301 has no particular pulmonary safety risks associated with this
particular inhalation system for patients in this PD population. Our data
support earlier CVT-301 studies, which showed that spirometry find-
ings were within normal ranges and were not significantly different
between CVT-301 and placebo over 4 weeks [10] and 12 weeks [7]. A
small proportion of screened patients (34/513, 6.6%) failed screening
because they were unable to perform spirometry in both the ON and
OFF states or had FEV1 ≥50% of predicted volume and FEV1/FVC
ratio> 60% in the ON state at screening. This may have biased the
study toward patients with better pulmonary function. As a compar-
ison, the study by Hampson et al. [9] reported that 8.2% of screened
patients were unable to achieve FEV1> 60% of predicted value and
FEV1/FVC ≥75% when ON, and an additional 3.0% were unable to
perform spirometry.








Patients, n (%) 73 (57.5) 192 (70.8)
Events, n 214 654
Serious TEAEs
Patients, n (%) 13 (10.2) 42 (15.5)
Events, n 18 61
Severe TEAEs
Patients, n (%) 9 (7.1) 36 (13.3)
Events, n 14 57
Drug-related TEAEs
Patients, n (%) – 102 (37.6)
Events, n – 209
TEAEs leading to study withdrawal
Patients, n (%) 0 24 (8.9)
Events, n 0 35
TEAEs occurring in ≥3% patients in any group, patients (%)
Cough 1 (0.8) 36 (13.3)
Fall 7 (5.5) 22 (8.1)
Nasopharyngitis 7 (5.5) 18 (6.6)
Dyskinesia 5 (3.9) 17 (6.3)
Upper respiratory tract infection 3 (2.4) 13 (4.8)
Back pain 4 (3.1) 12 (4.4)
Nausea 1 (0.8) 10 (3.7)
Hypertension 4 (3.1) 9 (3.3)
Sputum discolored 0 9 (3.3)
Throat irritation 0 9 (3.3)
Arthralgia 3 (2.4) 8 (3.0)
Parkinson's diseasea 4 (3.1) 8 (3.0)
Vertigo 0 8 (3.0)
Bronchitis 4 (3.1) 7 (2.6)
Orthostatic hypotension 4 (3.1) 7 (2.6)
Influenza 4 (3.1) 4 (1.5)
Insomnia 5 (3.9) 3 (1.1)
Musculoskeletal pain 4 (3.1) 3 (1.1)
PD, Parkinson's disease; TEAEs, treatment-emergent adverse events.
a Worsening of PD symptoms.
Fig. 2. Mean changes from baseline in FEV1 (A) and DLCO (B) over 12 months.
Note: Error bars represent standard deviation. Time points are staggered for
clarity. DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced
expiratory volume in 1 s.
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safety profile consistent with previous studies of CVT-301 and of oral
LD, except for mild transient cough associated with inhalation.
Exploratory efficacy measures showed improvement in UPDRS-III
scores 10 min after CVT-301 administration and this was sustained for
60 min. This pattern of improvement continued over the 12-month
study. Likewise, most patients achieved an ON state within 60 min
postdose, and patient PD diaries recorded 1.32–1.42-h reductions in
daily OFF time over the 52 weeks. These measures of efficacy were
supported by the PGIC results, which showed that> 75% of patients
reported improvement at each visit. A limitation of these efficacy re-
sults is the lack of a control population; the OC served as a control for
pulmonary safety rather than efficacy. Also, the power calculations did
not address the efficacy measures which were analyzed in an ex-
ploratory manner.
Patients were instructed not to take CVT-301 for early-morning OFF
periods (first OFF period of the day), so the usage was only 2.3 doses/
day, compared with the mean of 3.6 OFF periods/day observed at
baseline. A separate, randomized-crossover, single-dose study has ad-
dressed the administration of CVT-301 84 mg versus placebo for
treatment of early-morning OFF periods [19].
In conclusion, CVT-301 84 mg used for ≤12 months produced no
clinically significant differences in pulmonary function compared with
the OC. Improvements in motor scores, OFF time, and patient-reported
outcomes support clinical efficacy for ≤52 weeks of treatment.
Treatment of OFF periods remains an important unmet need for many
patients with PD, and this study supports the previously established
safety and efficacy of CVT-301 and confirms that it presents no sig-
nificant pulmonary safety concerns over 12 months in this population
of PD patients.
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